Novartis Earnings: Solid Results, but Generic Pressures Will Likely Decelerate Long-Term Growth

Novartis reported solid second-quarter results and slightly increased its full-year guidance, but these updates were largely in line with our projections, and we don’t expect any major changes to our fair value estimate. We continue to view the stock as largely fairly valued.